Johnson & Johnson has added another $10 to its price in two days, closing Tuesday at $271.11, yet the executive selling that defined last week's note has not stopped — and the gap between where insiders are exiting and where the stock now trades is widening.
The insider story has one more chapter since the last report. On August 17, EVP Jennifer Taubert sold 15,000 shares at $263.36 for $3.95 million. That follows CEO Joaquin Duato's $32.2 million in August 13 filings and the $12.5 million he disposed of on August 5 — bringing his nine-day total alone to roughly $44.7 million. The Chief Legal Officer added another $4.1 million on August 6. Across all executives, the 90-day net selling figure has now crossed $61 million with no purchases on record. The significance scores on each trade are low (2–3 out of 10), consistent with planned-disposal programmes, but the sheer volume of senior executives selling into a rising tape is the defining tension of this note. Taubert's transaction on the 17th came at $263 — the stock closed Tuesday at $271, roughly 3% above where she sold 48 hours earlier.
The market, for its part, is not listening to the selling. JNJ gained 4.4% on the week and 7.1% over the past month, reclaiming the $270 level for the first time since before the mid-July earnings dip. Analyst targets have been moving higher in tandem: Morgan Stanley raised its target to $294 after Q2 results, Wells Fargo lifted to $282, and Guggenheim bumped to $287 — all maintaining positive ratings. At $271, JNJ has essentially pulled level with the Street's consensus mean target of $272.50. Bulls point to immunology momentum and the optionality around the planned mid-2027 Orthopaedics separation. Bears flag the ovarian cancer litigation overhang and what happens to the earnings base once that separation completes. The PE runs at roughly 22x trailing and EV/EBITDA at 17.7x — not distressed, not cheap, but reasonable for a company generating this quality of cash flow.
Short sellers are not pressing the case. Short interest has fallen nearly 12% over the past week to 1.07% of the free float — already low, now lower. The lending market is completely unconstrained: borrow availability is effectively unlimited, and cost to borrow has ticked up modestly to 0.44% but remains trivially cheap. Options positioning is neutral and has tightened back toward its 20-day average PCR of 0.73, down from the more defensive readings above 0.90 that appeared in mid-July. None of the positioning signals point to any directional crowding — the longs own it, shorts have largely stepped aside, and options traders are not hedging aggressively. The next earnings date is October 13.
The question going into that October print is whether JNJ can sustain momentum above its consensus target without fresh positive catalysts, while its own executives continue to reduce exposure at prices well below where the stock now trades.
See the live data behind this article on ORTEX.
Open JNJ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
